Dialysis time: Does it matter? A reappraisal of existing literature

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 2, 2011, Pages 189-194

  Lacson Jr , Eduardo ^a   Lazarus, Michael ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

end stage renal disease; hemodialysis; mortality; outcomes; quality

Indexed keywords

PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; SODIUM; WATER;

ACUTE HEART INFARCTION; ARTICLE; ARTIFICIAL KIDNEY; BLOOD PRESSURE REGULATION; COST CONTROL; DIALYSIS MEMBRANE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOME DIALYSIS; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INTRACELLULAR MEMBRANE; INTRACELLULAR SPACE; KIDNEY CLEARANCE; MORTALITY; PATIENT ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM TRANSPORT; STROKE; SURVIVAL TIME; TREATMENT DURATION; ULTRAFILTRATION; WATER TRANSPORT;

BODY WATER; HUMANS; RENAL DIALYSIS; SODIUM; TIME FACTORS;

EID: 79952036407     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283432187     Document Type: Article

References (82)

1. Shibagaki M, Kolff WJ. In vitro and clinical studies of fluid removal with the Kiil dialyzer and subatmospheric-presure dialysate circuit. Cleve Clin Q 1965; 32:157-163.
2. De Palma JR. Adequate hemodialysis schedule. N Engl J Med 1971; 285:353.
3. Van Stone JC. Dialysis equipment and dialysate, past, present and the future. Semin Nephrol 1997; 17:214-217. (Pubitemid 27217174)
4. Gotch F, Lipps B, Weaver J Jr, et al. Chronic hemodialysis with the hollow fiber artificial kidney (HFAK). Trans Am Soc Artif Intern Organs 1969; 15:87-96.
5. Cheung AK, Leypoldt JK. The hemodialysis membranes: a historical perspective, current state and future prospect. Semin Nephrol 1997; 17:196-213. (Pubitemid 27217173)
6. Roy T, Ahrenholz P, Falkenhagen D, Klinkmann H. Volumetrically controlled ultrafiltration: current experiences and future prospects. Int J Artif Organs 1982; 5:131-135. (Pubitemid 12017270)
7. Graefe U, Milutinovich J, Follette WC, et al. Less dialysis-induced morbidity and vascular instability with bicarbonate in dialysate. Ann Intern Med 1978; 88:332-336. (Pubitemid 8287465)
8. Keshaviah P, Collins A. Rapid high-efficiency bicarbonate hemodialysis. ASAIO Trans 1986; 32:17-23.
9. Hilderson J, Ringoir S, van Waeleghem JP, et al. Short dialysis with a polyacrylonitrilmembrane (RP 6) without the use of a closed recirculating dialyzate delivery system. Clin Nephrol 1975; 4:18-22.
10. Alvarez-Ude F, Ward M, Elliott RW, et al. A comparison of short and long haemodialysis. Proc Eur Dial Transplant Assoc 1976; 12:606-613.
11. Trafford JA, Sharpstone P, Evans R, Ireland R. Evaluation of ultra-short dialysis. Br Med J 1979; 1:518-519. (Pubitemid 9114872)
12. Chapman GV, Mahony JF, Farrell PC. A crossover study of short time dialysis. Clin Nephrol 1980; 13:78-84. (Pubitemid 10069295)
13. Rotellar E, Martinez E, Samso JM, et al. Why dialyze more than 6 h a week? Trans Am Soc Artif Intern Organs 1985; 31:538-545.
14. Bosl R, Shideman JR, Meyer RM, et al. Effects and complications of high efficiency dialysis. Nephron 1975; 15:151-160.
15. Ward RA, Farrell PC, Tiller DJ, et al. A clinical evaluation of large-area shorttime haemodialysis. Aust N Z J Med 1976; 6:288-291.
16. Sellars L, Robson V, Wilkinson R. Sodium retention and hypertension with short dialysis. Br Med J 1979; 1:520-521. (Pubitemid 9114873)
17. Teschan PE, Ginn HE, Bourne JR, et al. A prospective study of reduced dialysis. ASAIO J 1983; 6:108-122. (Pubitemid 14186297)
18. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305:1176-1181. (Pubitemid 12237476)
19. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526-534. (Pubitemid 15248043)
20. Wauters JP, Bercini-Pansiot S, Gilliard N, Stauffer JC. Short hemodialysis: long-term mortality and morbidity. Artif Organs 1986; 10:182-184. (Pubitemid 16030084)
21. Rubin JE, Berlyne GM. Long-term follow-up of patients on short-time dialysis. ASAIO Trans 1987; 33:540-541.
22. Silverberg DS, Bettcher KB, Dossetor JB, et al. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy. Can Med Assoc J 1975; 112:190; 193-195.
23. Cunningham J. What is the optimal regimen for vitamin D? Kidney Int Suppl 1999; 73:S59-S64. (Pubitemid 30012830)
24. Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl 2005; 68:S2-S6.
25. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115-1125. (Pubitemid 41710323)
26. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992-1000. (Pubitemid 20034923)
27. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of endstage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78. (Pubitemid 17052741)
28. Charra B, Calemard E, Cuche M, Laurent G. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron 1983; 33:96-99. (Pubitemid 13190894)
29. Collins AJ, Kjellstrand CM. Shortening of the hemodialysis procedure and mortality in 'healthy' dialysis patients. ASAIO Trans 1990; 36:M145-M148. (Pubitemid 20367004)
30. Dumler F, Stalla K, Mohini R, et al. Clinical experience with short-time hemodialysis. Am J Kidney Dis 1992; 19:49-56.
31. Capelli JP, Kushner H, Camiscioli T, et al. Factors affecting survival of hemodialysis patients utilizing urea kinetic modeling: a critical appraisal of shortening dialysis times. Am J Nephrol 1992; 12:212-223. (Pubitemid 23010391)
32. Held PJ, Levin NW, Bovbjerg RR, et al. Mortality and duration of hemodialysis treatment. JAMA 1991; 265:871-875.
33. Blagg CR. The US renal data system and the case-mix severity study. Am J Kidney Dis 1993; 21:106-108. (Pubitemid 23062784)
34. Held PJ, Brunner F, Odaka M, et al. Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan 1982 to 1987. Am J Kidney Dis 1990; 15:451-457. (Pubitemid 20174015)
35. Held PJ, Blagg CR, Liska DW, et al. The dose of hemodialysis according to dialysis prescription in Europe and the United States. Kidney Int Suppl 1992; 38:S16-S21.
36. The Morbidity, Mortality and Prescription of Dialysis Symposium. Proceedings, Dallas, Texas, September 15-17, 1989. Am J Kidney Dis 1990 15 375-515.
37. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661-669. (Pubitemid 24138419)
38. Parker TF III, Husni L, Huang W, et al. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23:670-680. (Pubitemid 24138420)
39. Gotch FA, Levin NW, Port FK, et al. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997; 30:1-15. (Pubitemid 27284368)
40. Daugirdas JT, Depner TA, Gotch FA, et al. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney Int 1997; 52:1395-1405. (Pubitemid 27496071)
41. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010-2019. (Pubitemid 35461657)
42. Hassell DR, van der Sande FM, Kooman JP, et al. Optimizing dialysis dose by increasing blood flow rate in patients with reduced vascular-access flow rate. Am J Kidney Dis 2001; 38:948-955. (Pubitemid 33022171)
43. Depner TA, Greene T, Daugirdas JT, et al. Dialyzer performance in the HEMO Study: in vivo K0A and true blood flow determined from a model of crossdialyzer urea extraction. ASAIO J 2004; 50:85-93. (Pubitemid 38064006)
44. Bhimani JP, Ouseph R, Ward RA. Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and {beta}2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant 2010; 25:3990-3995.
45. Eloot S, Torremans A, De SR, et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 2005; 67:1566-1575. (Pubitemid 40463137)
46. Scharfetter H, Wirnsberger G, Hutten H, Holzer H. Development and critical evaluation of an improved comprehensive multicompartment model for the exchange processes during hemodialysis. Biomed Tech (Berl) 1995; 40:54-63.
47. Schneditz D, Daugirdas JT. Compartment effects in hemodialysis. Semin Dial 2001; 14:271-277. (Pubitemid 33720863)
48. Luik AJ, Charra B, Katzarski K, et al. Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Blood Purif 1998; 16:197-209. (Pubitemid 28458432)
49. Ly J, Chan CT. Impact of augmenting dialysis frequency and duration on cardiovascular function. ASAIO J 2006; 52:e11-e14. (Pubitemid 44784551)
50. Bogaard HJ, de Vries JP, de Vries PM. Assessment of refill and hypovolaemia by continuous surveillance of blood volume and extracellular fluid volume. Nephrol Dial Transplant 1994; 9:1283-1287. (Pubitemid 24283655)
51. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2010 [Epub ahead of print].
52. Brunet P, Saingra Y, Leonetti F, et al. Tolerance of haemodialysis: a randomized cross-over trial of 5-h versus 4-h treatment time. Nephrol Dial Transplant 1996; 11 (Suppl 8):46-51. (Pubitemid 27055725)
53. Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14:369-375. (Pubitemid 29062793)
54. McGregor DO, Buttimore AL, Lynn KL, et al. A comparative study of blood pressure control with short in-center versus long home hemodialysis. Blood Purif 2001; 19:293-300. (Pubitemid 32217841)
55. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69:1222-1228.
56. Troidle L, Hotchkiss M, Finkelstein F. A thrice weekly in-center nocturnal hemodialysis program. Adv Chronic Kidney Dis 2007; 14:244-248. (Pubitemid 46977283)
57. Lacson E Jr, Wang W, Lester K, et al. Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program. Clin J Am Soc Nephrol 2010; 5:220-226.
58. Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001-1006. (Pubitemid 23307908)
59. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69:1229-1236.
60. Miller JE, Kovesdy CP, Nissenson AR, et al. Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis 2010; 55:100-112.
61. Brunelli SM, Chertow GM, Ankers ED, et al. Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int 2010; 77:630-636.
62. Lacson E Jr, Diaz-Buxo JA. Daily and nocturnal hemodialysis: how do they stack up? Am J Kidney Dis 2001; 38:225-239.
63. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53:1399-1404. (Pubitemid 28316904)
64. Lockridge RS Jr, Spencer M, Craft V, et al. Nocturnal home hemodialysis in North America. Adv Ren Replace Ther 2001; 8:250-256. (Pubitemid 32954910)
65. Schwartz DI, Pierratos A, Richardson RM, et al. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol 2005; 63:202-208. (Pubitemid 40361259)
66. Tang HL, Wong JH, Poon CK, et al. One year experience of nocturnal home haemodialysis with an alternate night schedule in Hong Kong. Nephrology .2010. [Epub ahead of print].
67. Charra B. From adequate to optimal dialysis long 3- 8 hr dialysis: a reasonable compromise. Nefrologia 2005; 25 (Suppl 2):19-24.
68. Bugeja A, Dacouris N, Thomas A, et al. In-center nocturnal hemodialysis: another option in the management of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:778-783.
69. David S, Kumpers P, Eisenbach GM, et al. Prospective evaluation of an incentre conversion from conventional haemodialysis to an intensified nocturnal strategy. Nephrol Dial Transplant 2009; 24:2232-2240.
70. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16:2778-2788.
71. Eloot S, van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73:765-770. (Pubitemid 351323256)
72. Kjellstrand C, Buoncristiani U, Ting G, et al. Survival with short daily hemodialysis: association of time, site, and dose of dialysis. Hemodial Int 2010; 14:464-470.
73. Johansen KL, Zhang R, Huang Y, et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int 2009; 76:984-990.
74. Kliger AS. High-frequency hemodialysis: rationale for randomized clinical trials. Clin J Am Soc Nephrol 2007; 2:390-392.
75. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int 2007; 71:349-359. (Pubitemid 46227095)
76. Ramkumar N, Beddhu S, Eggers P, et al. Patient preferences for in-center intense hemodialysis. Hemodial Int 2005; 9:281-295. (Pubitemid 41131077)
77. Cafazzo JA, Leonard K, Easty AC, et al. Patient-perceived barriers to the adoption of nocturnal home hemodialysis. Clin J Am Soc Nephrol 2009; 4:784-789.
78. Pipkin M, Eggers PW, Larive B, et al. Recruitment and training for home hemodialysis: experience and lessons from the nocturnal dialysis trial. Clin J Am Soc Nephrol 2010; 5:1614-1620.
79. Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 2010; 75:49029-49214.
80. Bosch JP, Luckenbill L. Capitation in nephrology: the time has come. Adv Ren Replace Ther 1997; 4:325-331. (Pubitemid 27465042)
81. Nissenson AR. Models of capitated payment for endstage renal disease. Am J Med 2001; 110:504-505. (Pubitemid 32452344)
82. Lowell KH, Bertko J. The Accountable Care Organization (ACO) model: building blocks for success. J Ambul Care Manage 2010; 33:81-88.